Tag Archives: Novartis

Novartis eyes 3rd Kymriah indication with follicular lymphoma trial win

Novartis is hoping a third indication will help position Kymriah better against Gilead Sciences’ rival Yescarta in the CAR-T race—and it has positive early clinical results to back its case. Kymriah has hit its goal of eradicating signs of cancer in patients with relapsed or refractory follicular lymphoma (r/r FL) at an interim analysis of the phase 2 Elara… Read More »

Novartis offloads lagging endocrine drugs to Recordati for $390M

Novartis has been busy doing M&A to focus on higher-margin, innovative medicines under CEO Vas Narasimhan. Toward that goal, the Swiss drugmaker has taken another step and offloaded three endocrine drugs to Recordati. The drugs on the chopping board are Signifor, its long-acting sister Signifor LAR and in-development follow-up osilodrostat (LCI699). For the three of them,… Read More »

Novartis slaps $2M-plus pricetag on newly approved gene therapy Zolgensma—and cost watchdogs approve

Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer. The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of… Read More »

Did Novartis hand out kickbacks or host educational dinners? A jury may decide

Kickbacks, $ 10,000 dinners and Hooters. Details that sound pulled from an episode of Billions are key accusations in a federal lawsuit against Swiss drugmaker Novartis that could face a jury trial after a district judge’s order Monday. U.S. District Court Judge Paul Gardephe refused Novartis’ request for summary judgment in an 8-year-old lawsuit accusing… Read More »